Chemical Structure (Caplyta 1)
Caplyta Capsule
Product Images NDC 72060-110
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Caplyta (NDC 72060-110). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Intra-cellular Therapies, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1: Effects Of Intrinsic Factors On Lumateperone Pharmacokinetics (Caplyta 2)
Figure 2: Effects Of Other Drugs On Lumateperone Pharmacokinetics (Caplyta 3)
This appears to be a table showing fold change and 90% confidence intervals for different PK measures in relation to various drugs and inhibitors. The table includes information about CYP3A4 inhibitors and inducers, as well as UGT inhibitors, and their effects on Cmax and AUCt. The last row seems to show numerical values ranging from 0.008 to 40, which could potentially represent the fold change values. However, without proper context or headings, it is difficult to interpret this information accurately.*
Figure 3. Change From Baseline In Panss Total Score By Time (week) In Patients With Schizophrenia In Study 2. (Caplyta 4)
This is a graph that compares the number of patients between Placebo and CAPLYTA 42 mg over the course of several weeks, with the LS mean indicated.*
Principal Display Panel (42 mg Capsule Blister Pack Carton)
This is a statistical table displaying the LS mean change from baseline for a placebo and a drug called "CAPLYTA" at 42mg. The data is displayed over a period of 6 weeks for both the placebo and the drug groups. The number of patients for each group reduces from 188 to 166 for placebo and from 188 to 169 for CAPLYTA. The LS mean is the least squares mean.*
Principal Display Panel (42 mg Capsule Blister Pack Carton)
This is a description of a medication called Caplyta, which comes in capsule form with a strength of 42mg. The medication's NDC number is also provided. The description instructs to dispense the medication with the accompanying "Medi," but it is unclear what that refers to.*
Caplyta 7
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
